Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · BIOCRYST PHARMACEUTICALS INC (BCRX)

BioCryst Q2 revenue rises 34% to $218.3 million; raises 2026 revenue outlook

Positive Impact 4 of 5 earnings Written later

BioCryst reported second quarter 2026 total revenue of $218.3 million, up 34% from a year earlier, and GAAP net income of $78.4 million, or $0.30 per diluted share, compared with $5.1 million, or $0.02 per diluted share, a year earlier. The company raised its full year 2026 total revenue outlook to $690 million to $715 million and lowered its non-GAAP operating expense outlook to $420 million to $440 million, while keeping its ORLADEYO revenue outlook at $625 million to $645 million.

Key points

  • Q2 2026 total revenue $218.3 million (up 34% year over year); ORLADEYO revenue $158.2 million (up 1%)
  • GAAP operating profit $98.5 million in Q2 2026 versus $29.8 million in Q2 2025; non-GAAP operating profit $113.2 million
  • Full year 2026 total revenue outlook raised to $690 million to $715 million from $635 million to $660 million
  • Non-GAAP operating expense outlook lowered to $420 million to $440 million from $450 million to $470 million; six-month GAAP net loss of $643.4 million includes a $697.8 million acquired in-process R&D charge tied to the Astria acquisition

The filing

CompanyBIOCRYST PHARMACEUTICALS INC (BCRX)
Form8-K, current report
Filed with the SECAug 5, 2026, 7:02 AM ET
Accession number0001171843-26-005223

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:29 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.